Gri Bio Etf Current Valuation

GRI Etf  USD 0.96  0.04  3.76%   
Valuation analysis of GRI Bio helps investors to measure GRI Bio's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Fundamental drivers impacting GRI Bio's valuation include:
Price Book
1.9282
Enterprise Value
2.4 M
Trailing PE
0.0112
Undervalued
Today
0.96
Please note that GRI Bio's price fluctuation is abnormally volatile at this time. Calculation of the real value of GRI Bio is based on 3 months time horizon. Increasing GRI Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since GRI Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of GRI Etf. However, GRI Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  0.97 Real  2.29 Target  12.0 Hype  1.03 Naive  1.16
The intrinsic value of GRI Bio's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence GRI Bio's stock price.
2.29
Real Value
21.53
Upside
Estimating the potential upside or downside of GRI Bio helps investors to forecast how GRI etf's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of GRI Bio more accurately as focusing exclusively on GRI Bio's fundamentals will not take into account other important factors:
Earnings
Estimates (0)
LowProjectedHigh
-0.24-0.23-0.23
Details
Hype
Prediction
LowEstimatedHigh
0.051.0320.27
Details
Naive
Forecast
LowNext ValueHigh
0.021.1620.41
Details
1 Analysts
Consensus
LowTarget PriceHigh
10.9212.0013.32
Details

GRI Bio ETF Current Valuation Analysis

GRI Bio's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Enterprise Value

 = 

Market Cap + Debt

-

Cash

More About Current Valuation | All Equity Analysis

Current GRI Bio Current Valuation

    
  2.44 M  
Most of GRI Bio's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GRI Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Competition

In accordance with the recently published financial statements, GRI Bio has a Current Valuation of 2.44 M. This is much higher than that of the Biotechnology family and significantly higher than that of the Health Care category. The current valuation for all United States etfs is notably lower than that of the firm.

GRI Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GRI Bio's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of GRI Bio could also be used in its relative valuation, which is a method of valuing GRI Bio by comparing valuation metrics of similar companies.
GRI Bio is currently under evaluation in current valuation as compared to similar ETFs.

Fund Asset Allocation for GRI Bio

The fund invests 99.63% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.
Asset allocation divides GRI Bio's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.

GRI Fundamentals

About GRI Bio Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze GRI Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GRI Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GRI Bio based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in GRI Etf

GRI Bio financial ratios help investors to determine whether GRI Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GRI with respect to the benefits of owning GRI Bio security.